In the last trading session, 1.55 million Ocular Therapeutix Inc (NASDAQ:OCUL) shares changed hands as the company’s beta touched 1.36. With the company’s per share price at $7.51 changed hands at $0.29 or 4.02% during last session, the market valuation stood at $1.20B. OCUL’s last price was a discount, traded about -56.72% off its 52-week high of $11.77. The share price had its 52-week low at $4.79, which suggests the last value was 36.22% up since then.
Analysts gave the Ocular Therapeutix Inc (OCUL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OCUL as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Ocular Therapeutix Inc’s EPS for the current quarter is expected to be -0.35.
Ocular Therapeutix Inc (NASDAQ:OCUL) trade information
Instantly OCUL was in green as seen at the end of in last trading. With action 1.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -12.06%, with the 5-day performance at 1.62% in the green. However, in the 30-day time frame, Ocular Therapeutix Inc (NASDAQ:OCUL) is 2.74% up.
The consensus price target for the stock as assigned by Wall Street analysts is 19, meaning bulls need an upside of 60.47% from its current market value. According to analyst projections, OCUL’s forecast low is 19 with 19 as the target high. To hit the forecast high, the stock’s price needs a -153.0% plunge from its current level, while the stock would need to soar -153.0% for it to hit the projected low.
Ocular Therapeutix Inc (OCUL) estimates and forecasts
Year-over-year growth is forecast to reach -15.39% down from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 13.02M. 10 analysts are of the opinion that Ocular Therapeutix Inc’s revenue for the current quarter will be 13.97M. The company’s revenue for the corresponding quarters a year ago was 16.44M and 15.43M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -20.79%. The estimates for the next quarter sales put growth at -9.42%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.51%. The 2025 estimates are for Ocular Therapeutix Inc earnings to decrease by -18.16%, but the outlook for the next 5-year period is at 3.63% per year.
Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders
VR ADVISER, LLC holds the second largest percentage of outstanding shares, with 7.6964% or 12.76 million shares worth $87.3 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 4.64 shares estimated at $34.87 million under it, the former controlled 2.91% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.61% of the shares, roughly 4.16 shares worth around $31.25 million.
